Schaller Investment Group Inc decreased its stake in Credit Accep Corp Mich (CACC) by 14.21% based on its latest 2018Q4 regulatory filing with the SEC. Schaller Investment Group Inc sold 5,050 shares as the company’s stock rose 7.50% with the market. The hedge fund held 30,500 shares of the consumer services company at the end of 2018Q4, valued at $11.64M, down from 35,550 at the end of the previous reported quarter. Schaller Investment Group Inc who had been investing in Credit Accep Corp Mich for a number of months, seems to be less bullish one the $8.35 billion market cap company. The stock increased 1.01% or $4.39 during the last trading session, reaching $440.8. About 68,938 shares traded. Credit Acceptance Corporation (NASDAQ:CACC) has risen 39.26% since March 9, 2018 and is uptrending. It has outperformed by 34.89% the S&P500.
Wasatch Advisors Inc decreased its stake in Chemocentryx Inc (CCXI) by 2.76% based on its latest 2018Q4 regulatory filing with the SEC. Wasatch Advisors Inc sold 65,931 shares as the company’s stock rose 6.99% with the market. The institutional investor held 2.32M shares of the health care company at the end of 2018Q4, valued at $25.35M, down from 2.39 million at the end of the previous reported quarter. Wasatch Advisors Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $505.76M market cap company. The stock decreased 1.48% or $0.15 during the last trading session, reaching $10.01. About 170,627 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 9, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80
Investors sentiment decreased to 0.98 in Q4 2018. Its down 0.01, from 0.99 in 2018Q3. It is negative, as 20 investors sold CACC shares while 66 reduced holdings. 28 funds opened positions while 56 raised stakes. 10.05 million shares or 2.57% less from 10.32 million shares in 2018Q3 were reported. Schaller Group invested in 8.62% or 30,500 shares. The United Kingdom-based Hsbc Holdg Public Ltd Co has invested 0.08% in Credit Acceptance Corporation (NASDAQ:CACC). New York-based Ingalls And Snyder Limited Liability has invested 1.4% in Credit Acceptance Corporation (NASDAQ:CACC). Eqis Cap Mgmt has invested 0.11% in Credit Acceptance Corporation (NASDAQ:CACC). Rathbone Brothers Public Ltd Com has 0.01% invested in Credit Acceptance Corporation (NASDAQ:CACC) for 750 shares. State Street reported 0.01% in Credit Acceptance Corporation (NASDAQ:CACC). Teachers Retirement Of The State Of Kentucky owns 8,852 shares. Blair William Il has invested 0.03% in Credit Acceptance Corporation (NASDAQ:CACC). Susquehanna Intl Group Inc Limited Liability Partnership holds 0% or 16,746 shares in its portfolio. Moreover, Bokf Na has 0.03% invested in Credit Acceptance Corporation (NASDAQ:CACC). Bnp Paribas Asset Management Hldg Sa stated it has 0.02% of its portfolio in Credit Acceptance Corporation (NASDAQ:CACC). Of Toledo Na Oh, Ohio-based fund reported 699 shares. Cubist Systematic Strategies Ltd Liability has invested 0.01% in Credit Acceptance Corporation (NASDAQ:CACC). D E Shaw & Comm, New York-based fund reported 50,081 shares. Renaissance Technologies Ltd has 52,706 shares.
More notable recent Credit Acceptance Corporation (NASDAQ:CACC) news were published by: Nasdaq.com which released: “JPMorgan Evaluates Option to Establish Private Bank in China – Nasdaq” on March 01, 2019, also Nasdaq.com with their article: “4 Reasons to Invest in Credit Acceptance (CACC) Stock Now – Nasdaq” published on March 08, 2019, Gurufocus.com published: “6 Large-Cap Stocks Beating the Market – GuruFocus.com” on February 08, 2019. More interesting news about Credit Acceptance Corporation (NASDAQ:CACC) were released by: Gurufocus.com and their article: “Feb 08, 2019 – Credit Acceptance Corp (CACC) Files 10-K for the Fiscal Year Ended on December 31, 2018 – GuruFocus.com” published on February 08, 2019 as well as Globenewswire.com‘s news article titled: “Credit Acceptance Announces Third Quarter 2018 Earnings Nasdaq:CACC – GlobeNewswire” with publication date: October 29, 2018.
Analysts await Credit Acceptance Corporation (NASDAQ:CACC) to report earnings on May, 2. They expect $7.84 earnings per share, up 28.31% or $1.73 from last year’s $6.11 per share. CACC’s profit will be $148.48 million for 14.06 P/E if the $7.84 EPS becomes a reality. After $7.85 actual earnings per share reported by Credit Acceptance Corporation for the previous quarter, Wall Street now forecasts -0.13% negative EPS growth.
Since November 5, 2018, it had 0 buys, and 4 insider sales for $34.09 million activity. VASSALLUZZO SCOTT J sold $2.07 million worth of stock.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Announces Proposed Public Offering of Common Stock – GlobeNewswire” on September 26, 2018, also Seekingalpha.com with their article: “ChemoCentryx withdraws conditional approval application for avacopan in Europe – Seeking Alpha” published on January 24, 2019, Seekingalpha.com published: “ChemoCentryx launches $75M stock offering – Seeking Alpha” on September 26, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions â€” Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” published on February 26, 2019 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For February 11, 2019 – Benzinga” with publication date: February 11, 2019.
Since October 16, 2018, it had 0 insider purchases, and 8 insider sales for $87.64 million activity. On Friday, October 26 Cappel Markus J. sold $332,779 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 30,237 shares. KANAYA SUSAN M sold $457,747 worth of stock or 37,893 shares. $85.85M worth of stock was sold by GLAXOSMITHKLINE PLC on Tuesday, October 16.
Wasatch Advisors Inc, which manages about $19.28B and $7.50 billion US Long portfolio, upped its stake in Goosehead Ins Inc by 1.15 million shares to 1.30 million shares, valued at $34.08 million in 2018Q4, according to the filing. It also increased its holding in Knight Swift Transn Hldgs In by 380,422 shares in the quarter, for a total of 4.92 million shares, and has risen its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA).
Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It fall, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Wells Fargo & Mn stated it has 67,539 shares. J Goldman Ltd Partnership invested 0.04% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Sei holds 69,428 shares. 207,029 were reported by Baker Bros Advsr Lp. Farallon Cap Ltd Liability Com, California-based fund reported 1.45 million shares. Tiaa Cref Inv Mgmt Ltd Limited Liability Company invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Acadian Asset Ltd Liability Corp owns 0.04% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 818,489 shares. North Carolina-based State Bank Of America De has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). American International Group Inc holds 14,790 shares. Credit Suisse Ag holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 10,418 shares. Nantahala Capital Management Limited Liability Co stated it has 623,338 shares. Alliancebernstein Ltd Partnership holds 0% or 46,700 shares. Meeder Asset Mgmt has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Raymond James & Associate owns 12,174 shares or 0% of their US portfolio. Pnc Fincl Serv Group Inc reported 0% stake.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.